BHC
NYSEBausch Health Companies Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$6.74+0.03 (+0.45%)
01:30 PM07:45 PM
News · 26 weeks50-56%
2026-03-012026-08-23
Mix2190d
- Other9(43%)
- Insider7(33%)
- SEC Filings3(14%)
- Earnings2(10%)
Latest news
25 items- INSIDERPresident, US Pharma Lenar Aimee J. sold $258,894 worth of shares (36,827 units at $7.03), decreasing direct ownership by 10% to 334,853 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- PRA New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.Issued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time and gravity take away: fill a wrinkle, restore lost volume, reshape a contour. Now a shift in the underlying science is pointing toward something more ambitious. Instead of simply replacing volume, a growing body of research is asking whether the body's own tissue can be prompted to rebuild itself, and a new commercial category is beginning to form around that idea. At the center of the science is a structure most people have never heard of, the extracellular matrix, the frame
- PRBausch Health Announces 2026 Gastrointestinal Health Scholars Program WinnersFor the Seventh Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC, Aug. 17, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2026 Salix Gastrointestinal Health Scholars Program. For the seventh year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education."The extraordinary response to our scholarship program is a testament to the resilience, ambition, and perseverance of students living with gastrointestinal conditions," said Aimee Le
- PRBausch Health CEO Thomas J. Appio Joins Bausch + Lomb BoardLAVAL, QC, Aug. 6, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026."Bausch + Lomb is an important asset of Bausch Health, and I look forward to working with the board to support its strategy and help drive long-term value for shareholders," said Thomas J. Appio.In addition, Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi have joined the Bausch + Lomb board of directors. The new directors replace Steven Collis, Kare
- SECSEC Form 10-Q filed by Bausch Health Companies Inc.10-Q - Bausch Health Companies Inc. (0000885590) (Filer)
- SECBausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bausch Health Companies Inc. (0000885590) (Filer)
- PRBAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCESecond Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health of $258 million and GAAP Net Income of $260 millionGAAP Earnings per Diluted Share Attributable to Bausch Health of $0.68 compared to $0.40 in the prior year period; Adjusted Earnings per Diluted Share (non-GAAP)1 of $1.26 compared to $0.90 in the prior year period, an increase of 40%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1,075 million, up 28% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2026 RESULTSDelivered thi
- PR(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic DermatitisLAVAL, QC, July 28, 2026 /CNW/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) announces that PrELIDEL® (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible patients.ELIDEL® cream is indicated for second-line therapy for short-term and intermittent long-term therapy of mild to moderate atopic dermatitis in non-immunocompromised patients 3 months of age and older, in whom the use of alternative, conventional therapies is deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or intolerant of alternative, conventional therapies.1ELIDEL® has been available by
- INSIDERPresident, US Pharma Lenar Aimee J. covered exercise/tax liability with 5,260 shares, decreasing direct ownership by 1% to 371,680 units (SEC Form 4) (for withholding tax)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERPresident, US Pharma Lenar Aimee J. covered exercise/tax liability with 23,395 shares, decreasing direct ownership by 6% to 376,940 units (SEC Form 4) (tax liability)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERSVP, Controller & CAO Lee Steven Hyosig covered exercise/tax liability with 3,125 shares, decreasing direct ownership by 4% to 70,114 units (SEC Form 4) (tax withholding)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- PRBausch Health to Announce Second Quarter 2026 Results on July 29, 2026LAVAL, QC, July 7, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate: Wednesday, July 29, 2026Time: 5:00 p.m. U.S. EDTWebcast: http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available o
- PRQuébec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophreniaLAVAL, QC, July 6, 2026 /CNW/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), announces the listing of PrOKEDI® (extended-release injectable suspension of risperidone) 75 mg and 100 mg strengths to the drug formulary of the Régie de l'assurance maladie du Québec (RAMQ) effective June 25th, 2026, for the treatment of schizophrenia in adults.PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults. According to the Canadian product monograph, PrOKEDI® achieves clinically relevant concentrations of the active ingredient within the first few hours after injection, without the need
- INSIDERDirector Wechsler Amy B was granted 1,394 shares, increasing direct ownership by 0.44% to 314,979 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Paulson John was granted 12,677 shares, increasing direct ownership by 3% to 430,242 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Leung Sandra was granted 6,845 shares, increasing direct ownership by 8% to 97,070 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- SECBausch Health Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bausch Health Companies Inc. (0000885590) (Filer)
- PRMichael Goettler Resigns from Bausch Health's Board of DirectorsLAVAL, QC, July 1, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC."We thank Michael for his valued service and wish him the best in his new role," said John A. Paulson, Chairperson of the Bausch Health Board of Directors.Mr. Goettler's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutic
- PRBausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophreniaLAVAL, QC, June 9, 2026 /CNW/ -- Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), resulting in a Letter of Intent (LOI) for PrOKEDI® (Risperidone extended-release injectable suspension) 75mg and 100mg, a long-acting injectable antipsychotic agent for the treatment of schizophrenia in adults.1The issuance of this LOI marks a key milestone toward securing public coverage and enabling patient access to PrOKEDI® across Canada. Bausch Health remains committed to working closely with federal, provincial, and territorial public drug plans, to fin
- SECSEC Form SD filed by Bausch Health Companies Inc.SD - Bausch Health Companies Inc. (0000885590) (Filer)
- PRBausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in ChinaThermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands. This elite distinction—earned by only 217 brands across mainland China—recognizes
- INSIDERDirector Wechsler Amy B was granted 45,871 shares, increasing direct ownership by 17% to 313,585 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Roberts Eiry was granted 45,871 shares (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Power Robert N was granted 45,871 shares, increasing direct ownership by 18% to 300,594 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Paulson John was granted 45,871 shares, increasing direct ownership by 12% to 417,565 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
BHC FAQ
6 questionsWhat does Bausch Health Companies Inc. do?
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products...Where does BHC stock trade?
Bausch Health Companies Inc. (BHC) is listed on NYSE.What sector and industry is BHC in?
Bausch Health Companies Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BHC?
Bausch Health Companies Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $800.00 price target on 2025-12-09.What companies are similar to BHC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BHC side-by-side with any of them on Quantisnow.How can I track BHC on Quantisnow?
Quantisnow aggregates Bausch Health Companies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BHC to receive live email and push alerts on every new disclosure.